Qingqing Lukas Email & Phone Number

Washington, District Of Columbia, Us

Member of a team of 4 responsible for developing and executing on corporate M&A strategy for Danaher.

Washington, District Of Columbia, Us

Washington, District Of Columbia, Us

Tustin, Ca, Us

I founded the corporate BD group at Canon Medical System USA, and was responsible for partnering, investment, IP outlicensing, and M&A initiatives across all business units (CT, MRI, Molecular Imaging, Angiography, X-ray, Ultrasound, and Healthcare IT) across cutting-edge areas of medical imaging such as AI, IoT, and AR/VR. I also had ownership over the data & insights group, which supported strategic decision-making by product, service, and sales leadership at the country and corporate levels. In this role, I led a team of 5 analyst-to-manager level team members.

Tustin, Ca, Us

Los Angeles, California, Us

Reporting directly to the CEO, I led all strategic and external-facing initiatives for Neural Analytics (aka NovaSignal), including partnerships, financing, and investor relations. Example projects included executing on the end-to-end deal process for a multi-million dollar co-development partnership, driving due diligence efforts with 50+ VC/PE investors, and establishing a companion diagnostic strategy with biopharma companies for our technology platform across multiple neurology indications.

Boston, Massachusetts, Us

Prior to starting business school, I joined PureTech Health (LON: PRTC; NASDAQ: PRTC), a leading biotech venture capital / IP commercialization company in biopharma, medtech, and digital health, to explore the earlier phases of the life sciences product value chain. In this role, I worked with the CFO and Head of FP&A to develop a financial and strategic long-range plan for the organization, which was presented at Board of Directors meetings.

Newton, Ma, Us

Ranked as the #1 boutique consulting firm in the country according to Vault.com, ClearView Healthcare Partners partners with top biopharma & medical device companies on high-impact strategy projects. I entered the company as a Senior Analyst and was promoted to a post-MBA position (Consultant) in December 2015.During my time at ClearView, I gained extensive experience in strategic research and analysis in a diverse set of therapeutics areas . I supervised and mentored small teams on multi-week engagements with major biopharma clients. Example projects included devising a 10-year growth strategy for a ~$3B franchise of a top-5 biotech company, conducting due diligence for a large biotech client regarding potential acquisition of a ~$1B market cap company, and leading a market access landscape assessment for a ~$2B Medicare Part D drug. I also led market access-focused internal initiatives to bolster institutional payer knowledge, including providing new hire as well as ongoing training for ~80 consultants.

Newton, Ma, Us

Boston, Massachusetts, Us

The Ripples Group is a boutique public sector-focused consultancy created as an off-shoot of Bain & Company. In the role of Consultant, I aided the Director of MassHealth implement the Affordable Care Act in Massachusetts by developing health policies impacting 3+ million beneficiaries, coordinated evolving goals of 5+ internal & external stakeholders, and planned operational and IT workarounds. In addition, I spearheaded intensive operational efforts to launch Massachusetts Medical Marijuana Program, including producing a 150-page policy manual to guide the Executive Director on program rollout.

Cambridge, Massachusetts, Us

Under supervision of Dr. Jesse Snedeker, a world-renowned researcher in language acquisition, I undertook several projects examining the intersection between linguistics and neuroscience on topics of language acquisition and language processing.

Edmonton, Ab, Ca

I joined the West Research Group in Cardiac Transplantation as a part of the highly selective Heritage Youth Researcher Summer Program, funded by the Alberta government. Over three summers, I utilized advanced molecular biology techniques in an effort to determine the mechanism of ABO-incompatible transplantation. I was a contributing author to an article published in Transplantation (2010:90:282) and to a manuscript in submission to Journal of Clinical Investigation.

A.B., Neuroscience & Linguistics

Master Of Business Administration (Mba), Finance